Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Diosynth Signs Production Pact with VGX Pharma | Contract Pharma

What are you searching for?

Sign in
Breaking News

Diosynth Signs Production Pact with VGX Pharma

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Diosynth Biotechnology signed an agreement with VGX Pharmaceuticals for process development activities and cGMP production of clinical trial material for their biological drug candidate VGX-100 for the treatment of cancer.

VGX has developed technology using specific viral proteins that can induce selective apoptosis (programmed cell death) in rapidly dividing cancer cells, leaving normal cells unharmed. VGX-100, a recombinant viral protein, induces tumor cell death through apoptosis in number of tumor tissues including breast, prostate and brain. Initial trials will target patients with Non-Hodgkin’s Lymphoma and gastric cancer. Diosynth’s development and manufacturing program employs the Dowpharma Pfenex Expression Technology, a Pseudomonas-based technology that can increase yields of recombinant protein in biomanufacturing applications.

“We are excited to work with VGX Pharmaceuticals, an innovative and progressive biopharmaceutical company developing treatments for infectious and immunological diseases and cancer,” said Jacques van Kimmenaede, president of Diosynth Biotechnology.
“We are very interested in applying our skills in fermentation development and manufacturing for the production of VGX-100 and we are also very enthusiastic about using the Pfenex Expression Technology to do so.”

“We are pleased to have contracted Diosynth Biotechnology to manufacture VGX-100, given their extensive experience and broad capabilities in manufacturing of biologics and their commitment to high-quality cGMP manufacturing,” said J. Joseph Kim, Ph.D., president and chief executive officer of VGX Pharmaceuticals.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics